Cytosorbents Corp (CTS) 8-K Summary
Business Context and Reporting Period
Cytosorbents Corporation, a Delaware corporation, filed a Form 8-K Current Report on August 7, 2026, covering events reported as of August 6, 2026. The company is an emerging growth company with its principal executive offices in Princeton, New Jersey. Its common stock trades on the Nasdaq Capital Market under the symbol CTSO.
Financial Metrics
This filing is a Regulation FD disclosure and does not contain audited financial statements, revenue figures, profit data, cash flow metrics, margin analysis, debt levels, or liquidity ratios. The filing text does not provide a clear value for any specific financial metric.
Material Changes
The report does not detail specific material changes to financial performance or operations within the text of the 8-K itself. The filing serves to furnish an investor presentation (Exhibit 99.1) which is incorporated by reference but not included in the provided text.
Guidance, Outlook, and Risks
Management commentary, forward-looking guidance, and specific risk factors are contained within the attached Investor Presentation (Exhibit 99.1). The filing explicitly states that the information furnished is not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other registration statements. No unusual items or contingencies are described in the body of this report.
Key Facts for Investor Verification
- Verify the contents of Exhibit 99.1 (Investor Presentation) for actual financial data and strategic updates.
- Confirm the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Note that the information in this 8-K is "furnished" rather than "filed," limiting its legal liability under Section 18 of the Exchange Act.
- Check the Nasdaq Capital Market for the current trading status of CTSO common stock.